Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Class action filed
Appointed CFO
Quarterly results
Director departure
Appointed director
CC transcript
OCLARO, INC. (OCLR) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/04/2019 SC 13G/A Kopp Family Office, LLC reports a 0% stake in OCLARO, INC.
12/21/2018 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/10/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Agreement and Plan of Merger, by and among Oclaro, Inc., Lumentum Holdings Inc., Prota Merger Sub, Inc. and Prota Merger, LLC (incorporated by reference to the exhibit with the corresponding exhibit number in Oclaro's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2018)",
"Amended and Restated Certificate of Incorporation of Oclaro, Inc",
"Bylaws of Oclaro, Inc"
12/10/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
12/06/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"LUMENTUM ANNOUNCES RECEIPT OF ANTITRUST CLEARANCE IN CHINA AND EXPECTED CLOSING DATE OF ITS ACQUISITION OF OCLARO Milpitas, Calif., December 6, 2018 - Lumentum Holdings Inc. today announced, in connection with its pending acquisition of Oclaro, Inc. , that it has obtained antitrust clearance from the People's Republic of China's State Administration for Market Regulation. This clearance satisfies the acquisition's closing condition regarding the receipt of antitrust approval in the People's Republic of China. As such, Lumentum currently expects that the Oclaro acquisition will close on or around December 10, 2018. Cautionary Note Regarding Forward-Looking Statements The statement in this release regarding the expected closing date of the Oclaro acquisition is a forward-looking statement wi..."
11/08/2018 10-Q Quarterly Report for the period ended September 29, 2018
11/02/2018 425 Form 425 - Prospectuses and communications, business combinations:
10/25/2018 SC 13D/A Magnetar Financial LLC reports a 5% stake in Oclaro Inc
10/16/2018 GN Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
08/23/2018 10-K Annual Report for the period ended June 30, 2018
08/15/2018 GN Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group — Future Expectations, Projections Moving into 2018
08/13/2018 8-K Quarterly results
Docs: "Oclaro Announces Fourth Quarter and Fiscal Year 2018 Financial Results",
"Q417 Q118 Q218 Q318 Q418"
08/09/2018 425 Form 425 - Prospectuses and communications, business combinations:
07/23/2018 SC 13D Magnetar Financial LLC reports a 5% stake in Oclaro Inc
07/10/2018 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"About Oclaro"
06/29/2018 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 29, 2018 OCLARO, INC. Delaware 000-30684 20-1303994 225 Charcot Avenue, San Jose, California 95131 383-1400"
06/29/2018 425 Form 425 - Prospectuses and communications, business combinations:
06/20/2018 425 Form 425 - Prospectuses and communications, business combinations:
06/01/2018 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
05/31/2018 SD Form SD -
05/29/2018 GN Oclaro and Acacia Communications Collaborate on 100/200G CFP2-DCO Products
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy